Comparative Pharmacology
Head-to-head clinical analysis: ACYLANID versus LANOXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACYLANID versus LANOXIN.
ACYLANID vs LANOXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acylanid is a cardiac glycoside that inhibits the Na+/K+-ATPase pump, leading to increased intracellular sodium and calcium concentrations, which enhances myocardial contractility.
Inhibits Na+/K+ ATPase, increasing intracellular Ca2+ via Na+/Ca2+ exchange, enhancing cardiac contractility and reducing conduction through AV node.
0.1 mg IV bolus over 5 minutes, followed by 0.1 mg IV after 1 hour if needed; then 0.1-0.2 mg orally every 6-8 hours for maintenance. Maximum cumulative dose: 0.4 mg IV.
0.125-0.25 mg orally once daily; loading dose 0.5-0.75 mg orally divided over 24-48 hours if rapid digitalization required.
None Documented
None Documented
Terminal half-life 33–36 hours (anuric patients up to 110 hours); requires dose adjustment in renal impairment.
Terminal elimination half-life is approximately 36-48 hours in patients with normal renal function; prolonged to 3.5-5 days in anuria.
Renal (≈70% as unchanged drug), biliary/fecal (≈30%)
Renal excretion of unchanged drug (60-80%) and biliary/fecal elimination (20-40%).
Category C
Category C
Cardiac Glycoside
Cardiac Glycoside